Why the study?
Cardiovascular diseases remain a leading cause of global mortality, driving the need to develop innovative therapeutic agents such as honokiol.
Honokiol is a promising natural compound with pleiotropic cardiovascular benefits in preclinical models, warranting further research for clinical translation in cardiovascular disease management.
Does not support clinical use; leaves open translation of honokiol to cardiovascular trials.
Cardiovascular diseases (CVDs) remain a leading cause of global mortality. As the burden of these diseases continues to rise, the development of innovative therapeutic agents has become increasingly important. Honokiol, a bioactive compound extracted from the bark and leaves of particular Magnolia species, has garnered attention for its wide-ranging pharmacological effects, including anti-inflammatory, antioxidant, and vasodilatory properties. Emerging research suggests that honokiol holds significant promise as a therapeutic agent for managing CVDs. The present review provides a comprehensive overview of the bioactive properties, cardiovascular effects, mechanisms of action, and potential clinical utility of honokiol for the treatment of CVDs. Furthermore, challenges and future directions for the clinical translation of honokiol are discussed at length to provide additional context.
No takes yet. Share an insight, caveat, or question.
Zeng et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: